{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:18:34Z","timestamp":1793981914071,"version":"4.8.0"},"reference-count":135,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Remarkable progress in the understanding of disease pathogenesis and treatment across hematologic malignancies has been achieved in the past 2 decades. Nevertheless, the reliable elimination of disease remains elusive for many cancers. Chronic lymphocytic leukemia (CLL) exemplifies the needs that must be addressed to close the gap between discovery science and the remaining clinical challenges. In CLL, targeted therapies have substantially prolonged survival and enabled long-term disease control for many patients. However, curative outcomes remain exceptional, particularly in high-risk groups such as those with TP53 disruption, dual resistance to Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, or transformation to aggressive lymphoma. Recent insights into the interconnection between cancer and immunity have positioned CLL as a model example of cancer-associated immunodeficiency, a realization brought into sharp focus by the severe acute respiratory syndrome coronavirus 2 pandemic during which patients with CLL were at extremely high-risk for infection and poor outcomes. Therefore, complications related to infections, autoimmunity, and secondary cancers continue to contribute substantially to morbidity and mortality, underscoring the need for research on immune dysfunction in CLL. Furthermore, pronounced heterogeneity in disease progression and therapeutic resistance highlight the need for mechanistic studies to clarify these distinct biological patterns. Advances in these areas not only hold the promise of curative therapy for broader patient subgroups in CLL but will also inform innovation in research on other cancers, particularly in establishing a molecular definition of disease and defining those interactions with the underlying and resultant immune deficiencies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032393","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:54:39Z","timestamp":1776880479000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8674-1245","authenticated-orcid":false,"given":"Federico","family":"Caligaris-Cappio","sequence":"additional","affiliation":[{"name":"3AIRC Foundation for Cancer Research, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1023-6650","authenticated-orcid":false,"given":"Nicholas","family":"Chiorazzi","sequence":"additional","affiliation":[{"name":"4Hofstra Northwell School of Medicine, New Hyde Park, NY"},{"name":"5Feinstein Institutes for Medical Research, Manhasset, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-7430","authenticated-orcid":false,"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"6Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-4455","authenticated-orcid":false,"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"7University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"8The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-4549","authenticated-orcid":false,"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"9Moores Cancer Center, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7762","key":"2026070911211229600_bib2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","article-title":"Growth dynamics in naturally progressing chronic lymphocytic leukaemia","volume":"570","author":"Gruber","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026070911211229600_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"2026070911211229600_bib3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2026070911211229600_bib4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.2020010029","article-title":"Exploring the pathways to chronic lymphocytic leukemia","volume":"138","author":"Stevenson","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J Clin Invest"},{"issue":"24","key":"2026070911211229600_bib6","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"2026070911211229600_bib7","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026070911211229600_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2026070911211229600_bib9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2026070911211229600_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026070911211229600_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2026070911211229600_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjh.14285","article-title":"Pro-survival signal inhibition by CDK inhibitor dinaciclib in chronic lymphocytic leukaemia","volume":"175","author":"Chen","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"2026070911211229600_bib13","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"issue":"26","key":"2026070911211229600_bib14","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"2026070911211229600_bib15","doi-asserted-by":"crossref","first-page":"e163325","DOI":"10.1172\/JCI163325","article-title":"SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation","volume":"133","author":"Cusan","year":"2023","journal-title":"J Clin Invest"},{"issue":"3","key":"2026070911211229600_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/2643-3230.BCD-22-0156","article-title":"METTL3-mediated m6A modification controls splicing factor abundance and contributes to aggressive CLL","volume":"4","author":"Wu","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2026070911211229600_bib17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"3","key":"2026070911211229600_bib18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-13-0349","article-title":"Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia","volume":"4","author":"Oakes","year":"2014","journal-title":"Cancer Discov"},{"issue":"6","key":"2026070911211229600_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ccell.2014.10.012","article-title":"Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia","volume":"26","author":"Landau","year":"2014","journal-title":"Cancer Cell"},{"issue":"8081","key":"2026070911211229600_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41586-025-09374-4","article-title":"Fluctuating DNA methylation tracks cancer evolution at clinical scale","volume":"645","author":"Gabbutt","year":"2025","journal-title":"Nature"},{"issue":"7","key":"2026070911211229600_bib21","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Invest"},{"issue":"5","key":"2026070911211229600_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2026070911211229600_bib23","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"issue":"18","key":"2026070911211229600_bib24","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"22","key":"2026070911211229600_bib25","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2026070911211229600_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"2026070911211229600_bib27","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026070911211229600_bib28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clml.2025.07.012","article-title":"Survival outcomes in patients with chronic lymphocytic leukemia: a SEER analysis","volume":"26","author":"Modi","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026070911211229600_bib30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"21","key":"2026070911211229600_bib31","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2026070911211229600_bib32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib33","first-page":"11","article-title":"Richter syndrome: novel insights into the biology of transformation","volume":"142","author":"Parry","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000533234","article-title":"Immune dysfunction and infection - interaction between CLL and treatment: a reflection on current treatment paradigms and unmet needs","volume":"147","author":"Gargiulo","year":"2024","journal-title":"Acta Haematol"},{"issue":"10","key":"2026070911211229600_bib35","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/bloodadvances.2022008445","article-title":"Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026070911211229600_bib36","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2017.182006","article-title":"Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2026070911211229600_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers12020282","article-title":"Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs","volume":"12","author":"Vitale","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026070911211229600_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/17474086.2025.2523552","article-title":"Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia","volume":"18","author":"Bevilacqua","year":"2025","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"2026070911211229600_bib39","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.3324\/haematol.2020.248112","article-title":"Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents","volume":"106","author":"Barbaglio","year":"2021","journal-title":"Haematologica"},{"issue":"25","key":"2026070911211229600_bib40","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2021011993","article-title":"Understanding CLL biology through mouse models of human genetics","volume":"138","author":"Ten Hacken","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2026070911211229600_bib41","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3324\/haematol.2017.173419","article-title":"Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-kappaB inhibitor","volume":"102","author":"Vaisitti","year":"2017","journal-title":"Haematologica"},{"issue":"20","key":"2026070911211229600_bib42","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2026070911211229600_bib43","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2009-05-223586","article-title":"A novel Rag2-\/-gammac-\/--xenograft model of human CLL","volume":"115","author":"Bertilaccio","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2026070911211229600_bib44","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.2021013926","article-title":"Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib","volume":"139","author":"Purroyl","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026070911211229600_bib45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/10428194.2024.2422839","article-title":"Clinical trials in early-stage CLL: what has been learned and what's next?","volume":"66","author":"Hoechstetter","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2026070911211229600_bib46","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2026070911211229600_bib47","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest"},{"issue":"6","key":"2026070911211229600_bib99","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2026070911211229600_bib135","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2026070911211229600_bib48","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity","volume":"53","author":"Elsner","year":"2020","journal-title":"Immunity"},{"issue":"8","key":"2026070911211229600_bib49","doi-asserted-by":"crossref","first-page":"e20202489","DOI":"10.1084\/jem.20202489","article-title":"Germinal center-dependent and -independent memory B cells produced throughout the immune response","volume":"218","author":"Viant","year":"2021","journal-title":"J Exp Med"},{"issue":"11","key":"2026070911211229600_bib50","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"Klein","year":"2001","journal-title":"J Exp Med"},{"issue":"3","key":"2026070911211229600_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng.3488","article-title":"DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"2026070911211229600_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.seminhematol.2023.12.005","article-title":"B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: key to understanding disease biology and stratifying patients","volume":"61","author":"Agathangelidis","year":"2024","journal-title":"Semin Hematol"},{"issue":"12","key":"2026070911211229600_bib53","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood.2019001362","article-title":"Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk","volume":"134","author":"Sud","year":"2019","journal-title":"Blood"},{"key":"2026070911211229600_bib54","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1038\/ncomms14175","article-title":"Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia","volume":"8","author":"Law","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2026070911211229600_bib55","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/s41467-019-11582-2","article-title":"Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics","volume":"10","author":"Speedy","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"2026070911211229600_bib56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/bloodadvances.2021006941","article-title":"The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia","volume":"7","author":"Sun","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026070911211229600_bib58","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41467-023-36824-2","article-title":"LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1","volume":"14","author":"Vom Stein","year":"2023","journal-title":"Nat Commun"},{"issue":"19","key":"2026070911211229600_bib59","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","article-title":"Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia","volume":"118","author":"Yan","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2643-3230.BCD-22-0029","article-title":"Extracellular vesicle secretion by leukemia cells in vivo promotes CLL progression by hampering antitumor T-cell responses","volume":"4","author":"Gargiulo","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"2026070911211229600_bib61","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2026070911211229600_bib62","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood-2014-12-618470","article-title":"Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling","volume":"125","author":"Yeh","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2026070911211229600_bib63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2026070911211229600_bib64","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","article-title":"Mutation in Bruton tyrosine kinase (BTK) A428D confers resistance to BTK-degrader therapy in chronic lymphocytic leukemia","volume":"38","author":"Wong","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026070911211229600_bib65","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"6","key":"2026070911211229600_bib66","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","article-title":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","volume":"36","author":"Ghia","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026070911211229600_bib67","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"issue":"4","key":"2026070911211229600_bib110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/PPO.0000000000000536","article-title":"Mining the microenvironment for therapeutic targets in chronic lymphocytic leukemia","volume":"27","author":"Kipps","year":"2021","journal-title":"Cancer J"},{"issue":"6","key":"2026070911211229600_bib68","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41375-020-0714-3","article-title":"CRISPR\/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition","volume":"34","author":"Quijada-Alamo","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026070911211229600_bib69","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","article-title":"Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway","volume":"385","author":"Kwok","year":"2015","journal-title":"Lancet"},{"key":"2026070911211229600_bib70","doi-asserted-by":"crossref","first-page":"102026","DOI":"10.1016\/j.ctrv.2020.102026","article-title":"ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias","volume":"88","author":"Boudny","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2026070911211229600_bib71","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/s41418-020-0496-1","article-title":"NF-kappaB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia","volume":"27","author":"Sanchez-Lopez","year":"2020","journal-title":"Cell Death Differ"},{"issue":"25","key":"2026070911211229600_bib72","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2018-09-873695","article-title":"Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia","volume":"133","author":"Ghia","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026070911211229600_bib73","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3324\/haematol.2018.196931","article-title":"Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia","volume":"104","author":"Gim\u00e9nez","year":"2019","journal-title":"Haematologica"},{"issue":"40","key":"2026070911211229600_bib74","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1073\/pnas.1708264114","article-title":"MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia","volume":"114","author":"Rassenti","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2026070911211229600_bib75","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood.2021014760","article-title":"ROR1: an orphan becomes apparent","volume":"140","author":"Kipps","year":"2022","journal-title":"Blood"},{"key":"2026070911211229600_bib76","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcancer.2016.07.005","article-title":"NF-\u03baB activation in chronic lymphocytic leukemia: a point of convergence of external triggers and intrinsic lesions","volume":"39","author":"Mansouri","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"2026070911211229600_bib77","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"key":"2026070911211229600_bib78","doi-asserted-by":"crossref","first-page":"1169397","DOI":"10.3389\/fonc.2023.1169397","article-title":"NF-kB and the CLL microenvironment","volume":"13","author":"O'Donnell","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"2026070911211229600_bib79","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/cancers14061489","article-title":"Targeting the non-canonical NF-\u03baB pathway in chronic lymphocytic leukemia and multiple myeloma","volume":"14","author":"Burley","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"13","key":"2026070911211229600_bib80","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/blood.2019001366","article-title":"Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-\u03baB to repress autocrine STAT3 activation in chronic lymphocytic leukemia","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2026070911211229600_bib81","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J Exp Med"},{"issue":"7354","key":"2026070911211229600_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2026070911211229600_bib83","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1038\/s41467-018-06069-5","article-title":"Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia","volume":"9","author":"Mangolini","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2026070911211229600_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2011","journal-title":"Nat Genet"},{"issue":"5","key":"2026070911211229600_bib85","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/0008-5472.CAN-21-1843","article-title":"Cancer-associated SF3B1 mutations confer a BRCA-like cellular phenotype and synthetic lethality to PARP inhibitors","volume":"82","author":"Lappin","year":"2022","journal-title":"Cancer Res"},{"issue":"9","key":"2026070911211229600_bib86","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41375-024-02328-1","article-title":"Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition","volume":"38","author":"Chaudhry","year":"2024","journal-title":"Leukemia"},{"issue":"24","key":"2026070911211229600_bib87","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Mart\u00ednez-Trillos","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2026070911211229600_bib88","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/0008-5472.CAN-18-0781","article-title":"TLR signaling is activated in lymph node-resident CLL cells and is only partially inhibited by ibrutinib","volume":"79","author":"Dadashian","year":"2019","journal-title":"Cancer Res"},{"issue":"22","key":"2026070911211229600_bib89","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.2020005964","article-title":"TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib90","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","article-title":"Wnt\/\u03b2-catenin signaling in cancers and targeted therapies","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"2026070911211229600_bib91","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1080\/10428194.2021.1964020","article-title":"Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor","volume":"62","author":"Staber","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2026070911211229600_bib92","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2217\/fon-2022-0112","article-title":"Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review","volume":"18","author":"Davies","year":"2022","journal-title":"Future Oncol"},{"issue":"7","key":"2026070911211229600_bib93","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/leu.2014.32","article-title":"The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model","volume":"28","author":"Beckwith","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2026070911211229600_bib94","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026070911211229600_bib95","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2026070911211229600_bib96","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2026070911211229600_bib97","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2006-06-027755","article-title":"BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway","volume":"109","author":"Endo","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2026070911211229600_bib98","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1182\/blood.V85.12.3556.bloodjournal85123556","article-title":"Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells","volume":"85","author":"Ranheim","year":"1995","journal-title":"Blood"},{"key":"2026070911211229600_bib100","doi-asserted-by":"crossref","first-page":"584427","DOI":"10.3389\/fonc.2020.584427","article-title":"CD200 and chronic lymphocytic leukemia: biological and clinical relevance","volume":"10","author":"D'Arena","year":"2020","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"2026070911211229600_bib101","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2022-163353","article-title":"CLECL1+ CLL Cells: a key subset that drives CLL survival and proliferation and shapes a Th2-biased tumor microenvironment [abstract]","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026070911211229600_bib102","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib103","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2007-07-102350","article-title":"FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins","volume":"111","author":"Du","year":"2008","journal-title":"Blood"},{"issue":"15","key":"2026070911211229600_bib104","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1073\/pnas.1221841110","article-title":"Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026070911211229600_bib105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2009-08-237727","article-title":"Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"115","author":"Byrd","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib106","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1038\/s41467-024-48678-3","article-title":"Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia","volume":"15","author":"Nunes","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"2026070911211229600_bib107","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"2026070911211229600_bib108","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/1568009616666160809102219","article-title":"Functional and clinical significance of the integrin alpha chain CD49d expression in chronic lymphocytic leukemia","volume":"16","author":"Dal Bo","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"2026070911211229600_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"15","key":"2026070911211229600_bib111","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2022016279","article-title":"Progression and survival of MBL: a screening study of 10 139 individuals","volume":"140","author":"Slager","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026070911211229600_bib112","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2026070911211229600_bib113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41375-020-0799-8","article-title":"Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)","volume":"35","author":"Shanafelt","year":"2021","journal-title":"Leukemia"},{"issue":"15","key":"2026070911211229600_bib114","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.2020006322","article-title":"Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families","volume":"137","author":"Slager","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026070911211229600_bib115","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/leu.2014.226","article-title":"Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression","volume":"28","author":"Ojha","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2026070911211229600_bib116","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-022-01514-3","article-title":"Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis","volume":"36","author":"Boddicker","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026070911211229600_bib117","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.26388","article-title":"Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis","volume":"97","author":"Muchtar","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"2026070911211229600_bib118","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.177.4.925","article-title":"Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal","volume":"177","author":"Ranheim","year":"1993","journal-title":"J Exp Med"},{"issue":"3","key":"2026070911211229600_bib119","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.179.3.999","article-title":"Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells","volume":"179","author":"Lotz","year":"1994","journal-title":"J Exp Med"},{"issue":"9","key":"2026070911211229600_bib120","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nm0997-984","article-title":"Acquired CD40-ligand deficiency in chronic lymphocytic leukemia","volume":"3","author":"Cantwell","year":"1997","journal-title":"Nat Med"},{"issue":"1","key":"2026070911211229600_bib121","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2026070911211229600_bib122","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2008.07050.x","article-title":"Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait","volume":"141","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"2026070911211229600_bib123","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"2026070911211229600_bib124","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"9","key":"2026070911211229600_bib125","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2026070911211229600_bib126","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2026070911211229600_bib127","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \"nurselike\" cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","author":"Tsukada","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2026070911211229600_bib128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.seminhematol.2024.01.001","article-title":"Transforming CLL management with immunotherapy: investigating the potential of CAR T-cells and bispecific antibodies","volume":"61","author":"Borogovac","year":"2024","journal-title":"Semin Hematol"},{"issue":"1","key":"2026070911211229600_bib129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/hematology.2022000345","article-title":"Treatment of Richter's syndrome","volume":"2022","author":"Thompson","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"2026070911211229600_bib130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.2024028064","article-title":"International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations","volume":"146","author":"Kittai","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026070911211229600_bib131","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"2026070911211229600_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.08.013","article-title":"ZNF683 marks a CD8(+) T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome","volume":"41","author":"Parry","year":"2023","journal-title":"Cancer Cell"},{"issue":"8","key":"2026070911211229600_bib133","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"2026070911211229600_bib134","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3324\/haematol.2020.256388","article-title":"Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration","volume":"106","author":"Stephens","year":"2021","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/2\/175\/2531977\/blood_bld-2025-032393-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/2\/175\/2531977\/blood_bld-2025-032393-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:21:33Z","timestamp":1783610493000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/2\/175\/567916\/Unfinished-business-in-chronic-lymphocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032393","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,9]]},"published":{"date-parts":[[2026,7,9]]}}}